Diabetes Management Guidelines

American Association of Clinical Endocrinologists (AACE) Diabetes Guidelines 2013

 

Source: Reprinted with permission from American Association of Clinical Endocrinologists. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive Diabetes Management Algorithm. Endocr Pract. 2013;19(2):327-336. AACE guidelines for glycemic control, as well as obesity and cardiovascular disease, are available here.  

Summary recommendations for glycemic control based on guidelines from AACE are below.
These are summary recommendations provided for informational purposes. For full recommendations, view the original reference source.

To start, select your patient’s baseline A1C:

<7.5% → Begin at Monotherapy 

≥7.5% → Begin at Dual Therapy 

>9.0% with No Symptoms → Begin at Dual Therapy or Triple Therapy 

>9.0% with Symptoms → Insulin ± Other Agents: Begin at Start Basal(Long-Acting) Insulin or Intensify Insulin (Add Short-Acting Insulin; Prandial Control)
 

 A1C Targets 
Click on the links below to expand the recommendations for each section.
Click on the button at the bottom of each section to move through treatment recommendations for your patient.
 
 

Monotherapy  

Dual Therapy  

Triple Therapy  

Start Basal (Long-Acting) Insulin  

Intensify Insulin (Add Short-Acting Insulin; Prandial Control)  

These are summary recommendations provided for informational purposes. For full recommendations, view the original reference source.

BG=blood glucose; DPP-4 inhibitor=dipeptidyl peptidase-4 inhibitor; FBG=fasting blood glucose; GLP-1 receptor agonist=glucagon-like peptide-1 receptor agonist; NPH=neutral protamine Hagedorn; QR=quick release; SGLT2 inhibitor=sodium-glucose co-transporter 2 inhibitor; TZD=thiazolidinedione

The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States. 

 July 2013   

This content was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest. 

Back to
Clinical Guidelines 

BG Footer

Last Modified: 3/10/2014

Notice About Sponsored Content Clicking the banners below will direct you to sponsored content. KnowledgePoint360 does not endorse and bears no responsibility for sponsored content hosted on NDEI.org. For more information, please read our Editorial Policy

Advertisement